SCHEMBL16924924

SCHEMBL16924924

CC(C)Oc1ccc(C(=O)CF)cc1N

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 2/20 0.45
CREBBP Q92793 1/20 0.44
PDE4B Q07343 1/20 0.42
TUBB4A P04350 1/20 0.42
TUBB P07437 1/20 0.42
TUBA3C P0DPH7 1/20 0.42
TUBA1B P68363 1/20 0.42
TUBA4A P68366 1/20 0.42
TUBB4B P68371 1/20 0.42
TUBB3 Q13509 1/20 0.42
TUBB2A Q13885 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18232135 0.81 CREBBP (0.61) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL31510251 0.81 CREBBP (0.61) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL10304691 0.81 KMT2A (0.53) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL6112896 0.81 PARP10 (0.56) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL2630553 0.80 EP300 (0.50) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL16924940 0.79 MLYCD (0.46) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL7482554 0.79 PDE4B (0.42) PDE4BACHEPDK1
SCHEMBL1788246 0.78 USP2 (0.61) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL6114150 0.78 CA12 (0.54) USP2NPC1RAB9ASMN1; SMN2HSD17B10
SCHEMBL31439512 0.78 PDE4B (0.46) USP2NPC1RAB9ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938245-B2 Carbonyl erastin analogs and their use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-04-10 US disclosed
US-9938245-B2 Carbonyl erastin analogs and their use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-04-10 US disclosed
US-20160332974-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2016-11-17 US disclosed
US-20160332974-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2016-11-17 US disclosed
WO-2015109009-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332974-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE KEAP1, GPX1, GPX4 USP2 775/4885NPC1 2280/4885RAB9A 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.